| Reference |
|
5109
Chien CH1, Wang FF, Hamilton TC.
Transcriptional activation of c-myc proto-oncogene by estrogen in human ovarian cancer cells.
Mol Cell Endocrinol
1994
99(1):11-9
PubMed ID: 8187952
DOI: 10.1016/0303-7207(94)90140-6
|
|
5108
Kanemoto T1, Martin GR, Hamilton TC, Fridman R.
Effects of synthetic peptides and protease inhibitors on the interaction of a human ovarian cancer cell line (NIH:OVCAR-3) with a reconstituted basement membrane (Matrigel).
Invasion Metastasis
1991
11(2):84-92
PubMed ID: 1917387
|
|
5107
Nash JD1, Ozols RF, Smyth JF, Hamilton TC.
Estrogen and anti-estrogen effects on the growth of human epithelial ovarian cancer in vitro.
Obstet Gynecol
1989
73(6):1009-16
PubMed ID: 2542854
DOI: 10.1097/00006250-198906000-00021
|
|
5104
Ozols RF, Louie KG, Plowman J, Behrens BC, Fine RL, Dykes D, Hamilton TC.
Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione.
Biochem Pharmacol
1987
36(1):147-53
PubMed ID: 3801051
DOI: 10.1016/0006-2952(87)90392-3
|
|
5105
FitzGerald DJ, Bjorn MJ, Ferris RJ, Winkelhake JL, Frankel AE, Hamilton TC, Ozols RF, Willingham MC, Pastan I.
Antitumor activity of an immunotoxin in a nude mouse model of human ovarian cancer.
Cancer Res
1987
47(5):1407-10
PubMed ID: 3493065
|
|
5106
Holt JA, Waggoner SE, Lee EY, Hubby MM, Hamilton TC.
Serum CA 125 and survival of mice inoculated with ovarian carcinoma and treated with antiestrogen, estrogen, or progestin.
Gynecol Oncol
1987
27(3):282-93
PubMed ID: 3476351
DOI: 10.1016/0090-8258(87)90248-4
|
|
5102
Green JA, Vistica DT, Young RC, Hamilton TC, Rogan AM, Ozols RF.
Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion.
Cancer Res
1984
44(11):5427-31
PubMed ID: 6488194
|
|
5103
Hamilton TC, Young RC, Louie KG, Behrens BC, McKoy WM, Grotzinger KR, Ozols RF.
Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice.
Cancer Res
1984
44(11):5286-90
PubMed ID: 6333272
|
|
5101
Hamilton TC, Young RC, McKoy WM, Grotzinger KR, Green JA, Chu EW, Whang-Peng J, Rogan AM, Green WR, Ozols RF.
Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors.
Cancer Res
1983
43(11):5379-89
PubMed ID: 6604576
|
| User's Publication |
|
17883
Okano F, Saito T, Minamida Y, Kobayashi S, Ido T, Miyauchi Y, Wasai U, Akazawa D, Kume M, Ishibashi M, Jiang K, Aicher A, Heeschen C, Yonehara T.
Identification of Membrane-expressed CAPRIN-1 as a Novel and Universal Cancer Target, and Generation of a Therapeutic Anti-CAPRIN-1 Antibody TRK-950
Cancer Res Commun
2023
3(4):640-658
PubMed ID: 37082579
DOI: 10.1158/2767-9764.CRC-22-0310
|
|
19782
Kido K, Nojima S, Motooka D, Nomura Y, Kohara M, Sato K, Ohshima K, Tahara S, Kurashige M, Umeda D, Takashima T, Kiyokawa H, Ukon K, Matsui T, Okuzaki D, Morii E.
Ovarian high-grade serous carcinoma cells with low SMARCA4 expression and high SMARCA2 expression contribute to platinum resistance
J Pathol
2023
260(1):56-70
PubMed ID: 36763038
DOI: 10.1002/path.6064
|
|
21318
Hoshino H, Chen YY, Inoue D, Yoshida Y, Khoo KH, Akama TO, Kobayashi M.
Expression of low-sulfated keratan sulfate in non-mucinous ovarian carcinoma.
Glycobiology
2023
PubMed ID: 37440446
DOI: 10.1093/glycob/cwad056
|
|
21426
Machino H, Dozen A, Konaka M, Komatsu M, Nakamura K, Ikawa N, Shozu K, Asada K, Kaneko S, Yoshida H, Kato T, Nakayama K, Saloura V, Kyo S, Hamamoto R.
Integrative analysis reveals early epigenetic alterations in high-grade serous ovarian carcinomas.
Exp Mol Med
2023
PubMed ID: 37779141
DOI: 10.1038/s12276-023-01090-1
|
|
21483
Tsuchimochi S, Wada-Hiraike O, Urano Y, Kukita A, Yamaguchi K, Honjo H, Taguchi A, Tanikawa M, Sone K, Mori-Uchino M, Tsuruga T, Oda K, Osuga Y.
Characterization of a fluorescence imaging probe that exploits metabolic dependency of ovarian clear cell carcinoma.
Sci Rep
2023
13(1):20292
PubMed ID: 37985723
DOI: 10.1038/s41598-023-47637-0
|
|
17525
Iwahashi N, Ikezaki M, Komohara Y, Fujiwara Y, Noguchi T, Nishioka K, Sakai K, Nishio K, Ueda M, Ihara Y, Uchimura K, Ino K, Nishitsuji K.
Cytoplasmic p53 aggregates accumulated in p53-mutated cancer correlate with poor prognosis
PNAS Nexus
2022
1(3):pgac128
PubMed ID: 36741442
DOI: 10.1093/pnasnexus/pgac128
|
|
18224
Sadahiro Y, Hitora Y, Kimura I, Hitora-Imamura N, Onodera R, Motoyama K, Tsukamoto S.
Colletofragarone A2 Inhibits Cancer Cell Growth In Vivo and Leads to the Degradation and Aggregation of Mutant p53
Chem Res Toxicol
2022
35(9):1598-1603
PubMed ID: 36027604
DOI: 10.1021/acs.chemrestox.2c00202
|
|
20521
Machino H, Kaneko S, Komatsu M, Ikawa N, Asada K, Nakato R, Shozu K, Dozen A, Sone K, Yoshida H, Kato T, Oda K, Osuga Y, Fujii T, von Keudell G, Saloura V, Hamamoto R.
The metabolic stress-activated checkpoint LKB1-MARK3 axis acts as a tumor suppressor in high-grade serous ovarian carcinoma.
Commun Biol
2022
5(1):39
PubMed ID: 35017636
DOI: 10.1038/s42003-021-02992-4
|
|
20745
Kobayashi T, Mitsuhashi A, Hongying P, Shioya M, Kojima K, Nishikimi K, Yahiro K, Shozu M.
Bexarotene-induced cell death in ovarian cancer cells through Caspase-4-gasdermin E mediated pyroptosis.
Sci Rep
2022
12(1):11123
PubMed ID: 35778597
DOI: 10.1038/s41598-022-15348-7
|
|
20938
Kanda M, Serada S, Hiramatsu K, Funauchi M, Obata K, Nakagawa S, Ohkawara T, Murata O, Fujimoto M, Chiwaki F, Sasaki H, Ueda Y, Kimura T, Naka T.
Lipolysis-stimulated lipoprotein receptor-targeted antibody-drug conjugate demonstrates potent antitumor activity against epithelial ovarian cancer.
Neoplasia
2022
35:100853
PubMed ID: 36413881
DOI: 10.1016/j.neo.2022.100853
|
|
17524
Iwahashi N, Ikezaki M, Fujimoto M, Komohara Y, Fujiwara Y, Yamamoto M, Mizoguchi M, Matsubara K, Watanabe Y, Matsuzaki I, Murata SI, Ihara Y, Ino K, Nishitsuji K.
Lipid Droplet Accumulation Independently Predicts Poor Clinical Prognosis in High-Grade Serous Ovarian Carcinoma
Cancers (Basel)
2021
13(20):5251
PubMed ID: 34680399
DOI: 10.3390/cancers13205251
|
|
9937
Ryosuke Koyama, Yui Kano, Kaori Kikushima, Ayaka Mizutani, Yuta Soeda, Kazuki Miura, Takako Hirano, Toshiyuki Nishio, Wataru Hakamata
A Novel Golgi Mannosidase Inhibitor: Molecular Design, Synthesis, Enzyme Inhibition, and Inhibition of Spheroid Formation
Bioorg Med Chem
2020
28(11):115492
PubMed ID: 32291147
DOI: 10.1016/j.bmc.2020.115492
|
|
20125
Iwahashi N, Ikezaki M, Nishikawa T, Namba N, Ohgita T, Saito H, Ihara Y, Shimanouchi T, Ino K, Uchimura K, Nishitsuji K.
Sulfated glycosaminoglycans mediate prion-like behavior of p53 aggregates.
Proc Natl Acad Sci U S A
2020
117(52):33225-33234
PubMed ID: 33318190
DOI: 10.1073/pnas.2009931117
|
|
14832
Saito S, Kitamura-Muramatsu Y, Komine F, Polat M, Takeshima SN, Takei M, Aida Y.
Absence of bovine leukemia virus proviral DNA in Japanese human blood cell lines and human cancer cell lines
Arch Virol
2020
165(1):207-214
PubMed ID: 31776677
DOI: 10.1007/s00705-019-04474-9
|
|
12529
Mase S, Shinjo K, Totani H, Katsushima K, Arakawa A, Takahashi S, Lai HC, Lin RI, Chan MWY, Sugiura-Ogasawara M, Kondo Y.
ZNF671 DNA methylation as a molecular predictor for the early recurrence of serous ovarian cancer
Cancer Sci
2019
110(3):1105-1116
PubMed ID: 30633424
DOI: 10.1111/cas.13936
|
|
9868
Ito H, Yamaguchi N, Onimaru M, Kimura S, Ohmori T, Ishikawa F, Sato J, Ito S, Inoue H.
Change in number and size of circulating tumor cells with high telomerase activity during treatment of patients with gastric cancer.
Oncol Lett
2016
12:4720-4726
PubMed ID: 28105179
DOI: 10.3892/ol.2016.5239
|
|
9899
Saito KI, Inoue Y, Ikegami Y, Nanbo I, Onozuka M, Sano K, Yoshida H, Sakamoto T, Tatebayashi E, Fujita KI, Sasaki Y, Kitazawa T.
Investigation of Bioequivalence Between Brand-name and Generic Irinotecan Products.
Anticancer Res.
2016
36:5957-5963
PubMed ID: 27793921
DOI: 10.21873/anticanres.11183
|
|
15130
Asanuma D, Sakabe M, Kamiya M, Yamamoto K, Hiratake J, Ogawa M, Kosaka N, Choyke PL, Nagano T, Kobayashi H, Urano Y.
Sensitive β-galactosidase-targeting fluorescence probe for visualizing small peritoneal metastatic tumours in vivo
Nat Commun
2015
6:6463
PubMed ID: 25765713
DOI: 10.1038/ncomms7463
|
|
18284
Davidson BA, Rubatt JM, Corcoran DL, Teoh DK, Bernardini MQ, Grace LA, Soper WJ, Berchuck A, Siamakpour-Reihani S, Chen W, Owzar K, Murphy SK, Secord AA.
Differential Angiogenic Gene Expression in TP53 Wild-Type and Mutant Ovarian Cancer Cell Lines
Front Oncol
2014
4:163
PubMed ID: 24999452
DOI: 10.3389/fonc.2014.00163
|
|
13706
Yamaguchi S, Maida Y, Yasukawa M, Kato T, Yoshida M, Masutomi K.
Eribulin mesylate targets human telomerase reverse transcriptase in ovarian cancer cells
PLoS One
2014
9(11):e112438
PubMed ID: 25375122
DOI: 10.1371/journal.pone.0112438
|
|
18273
Alvarez Secord A, Bernardini MQ, Broadwater G, Grace LA, Huang Z, Baba T, Kondoh E, Sfakianos G, Havrilesky LJ, Murphy SK.
TP53 Status is Associated with Thrombospondin1 Expression In vitro
Front Oncol
2013
3:269
PubMed ID: 24195060
DOI: 10.3389/fonc.2013.00269
|
|
9669
Ikue Nakayama, Masahiko Shibazaki, Akiko Yashima-Abo, Fumiharu Miura, Toru Sugiyama, Tomoyuki Masuda, Chihaya Maesawa
Loss of HOXD10 Expression Induced by Upregulation of miR-10b Accelerates the Migration and Invasion Activities of Ovarian Cancer Cells
Int J Oncol
2013
43(1):63-71
PubMed ID: 23670532
DOI: 10.3892/ijo.2013.1935
|
|
14401
Yamaguchi Y, Deng D, Sato Y, Hou YT, Watanabe R, Sasaki K, Kawabe M, Hirano E, Morinaga T.
Silicate fiber-based 3D cell culture system for anticancer drug screening
Anticancer Res
2013
33(12):5301-9
PubMed ID: 24324063
|
|
7849
Yoshida H, Sumi T, Zhi X, Yasui T, Honda K, Ishiko O.
Claudin-4: a potential therapeutic target in chemotherapy-resistant ovarian cancer.
Anticancer Res.
2011
31:1271-7
PubMed ID: 21508375
|
|
7910
Masuishi Y, Arakawa N, Kawasaki H, Miyagi E, Hirahara F, Hirano H.
Wild-type p53 enhances annexin IV gene expression in ovarian clear cell adenocarcinoma.
FEBS J.
2011
278:1470-83
PubMed ID: 21348943
DOI: 10.1111/j.1742-4658.2011.08059.x
|
|
18789
Kikuchi T, Ishii K, Noto T, Takahashi A, Tabata K, Suzuki T, Akihisa T.
Cytotoxic and apoptosis-inducing activities of limonoi
J Nat Prod
2011
74(4):866-70
PubMed ID: 21381696
DOI: 10.1021/np100783k
|
|
8169
Egawa-Takata T, Endo H, Fujita M, Ueda Y, Miyatake T, Okuyama H, Yoshino K, Kamiura S, Enomoto T, Kimura T, Inoue M.
Early reduction of glucose uptake after cisplatin treatment is a marker of cisplatin sensitivity in ovarian cancer.
Cancer Sci.
2010
101:2171-8
PubMed ID: 20678156
DOI: 10.1111/j.1349-7006.2010.01670.x
|
Back
Top
CELL BANK Website
